

Segolene Hescot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2811186/publications.pdf>

Version: 2024-02-01

8
papers

322
citations

1478505

6
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

659
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of expert review of histological diagnosis of papillary and follicular thyroid cancer. <i>Endocrine</i> , 2021, 72, 791-797.	2.3	8
2	Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2726-2737.	3.6	8
3	ALK Rearrangement in Lung Neuroendocrine Neoplasms: Case Series of Non-Asian Patients With Response to ALK Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, e686-e690.	2.6	6
4	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2367-2374.	3.6	103
5	Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1772-1780.	6.4	62
6	Dyslipidemia causes overestimation of plasma mitotane measurements. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, 150135.	0.5	3
7	Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2890-2898.	3.6	30
8	One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4006-4012.	3.6	102